BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix ™ Catheter SUNNYVALE, Calif. – October 1, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea
How this was made
The 30-second read
Why it matters
The revised De Novo submission is a key step toward market clearance, which could unlock partnership opportunities and revenue growth.
Market read
Regulatory progress for a novel cardiac delivery device may drive short‑term stock movement and longer‑term sector interest.
What to watch
Potential competition from other catheter technologies and the need for additional clinical data beyond the current 15 trials.
Background
BioCardia is a Nasdaq‑listed developer of cell‑derived therapeutics and delivery platforms for cardiac applications.
Ticker impact
BioCardia filed a revised De Novo pre‑submission to the FDA for its Helix catheter, a first‑time regulatory filing disclosed in this 8‑K.
likely upward pressure as investors price in the chance of clearance
Regulatory milestones for medical devices are material catalysts; the FDA has not raised concerns and the review timeline is short.
Market effects
Positive signal for the cardiovascular device sector, may boost peers developing similar delivery platforms.
Limited to U.S. biotech and med‑tech investors; no broader regional effect.
Modest global relevance, primarily affecting U.S. listed biotech equities.
Counterpoint
If the FDA delays or denies clearance, the stock could face sharp downside; investors should watch the 70‑day review window.
Key entities
- companyBioCardia, Inc.
Nasdaq‑listed developer of the Helix catheter and cardiac cell therapies.
